Non-Small Cell Lung Cancer Therapeutics Market, By Drug Class (ALECENSA, Alimta, Avastin, Cyramza, Iressa, Opdivo, Tagrisso, Tarceva, Xalkori, and Zykadia), By Cancer Type (Adenocarcinoma, Large cell carcinoma, and Squamous Cell Carcinoma), By Distribution Channel (Hospital Pharmacy, Online Channels, and Retail Pharmacy), and By Geography Analysis, Size, Share, Trends, & Forecast from 2021-2027
REPORT HIGHLIGHT
The global non-small cell lung cancer therapeutics market was valued at USD 7.83 billion by 2019, growing with 7.2% CAGR during the forecast period, 2021-2027.
Non-small cell lung cancer therapeutics are the drugs that are given to the patient suffering from a lung tumor. The NSCLC can be categorized into adenocarcinoma starts, squamous cell carcinoma, and large cell carcinoma. This cancer majorly affects the people who smoke or have been around smoke. Its treatment includes medications comprising chemotherapy, a medical procedure including stereotactic radiation therapy and radiation therapy, and surgery accounting for surgical removal of part of the lung, pulmonary lobectomy, and pneumonectomy.
Market Dynamics
The NSCLC therapeutics market witnessed steady growth and will speed up in the next decade, owing to the increasing prevalence of cancer coupled with the expected introduction of several drugs in the market. Increasing air pollution and the changing lifestyle habits, in terms of drinking and smoking, are the factors responsible for increasing the patient population diagnosed with NSCLC, which in turn, favors the global non-small cell lung cancer therapeutics market growth. For instance, the report published by the American Cancer Society’s, in January 2020, estimated the total count of citizens suffering from lung cancer in the United States to be about 228,820 among which 84% accounted to be diagnosed with NSCLC.
Furthermore, the increasing investments by the key players for product research and development activities along with the strong pipeline also boost the global non-small cell lung cancer therapeutics market potential. However, the pricing pressure among manufacturers coupled with the introduction of generics medicines may hamper the industry growth. Besides, the side effects linked with the drugs are the global non-small cell lung cancer therapeutic markets challenge those slowdowns the business is growing in the upcoming years.
Drug Class Takeaway
Depending upon drug class, the global business is categorized into ALECENSA (alectinib), Alimta (pemetrexed), Avastin (bevacizumab), Cyramza (ramucirumab), Iressa (gefitinib), Opdivo (nivolumab), Tagrisso (osimertinib), Tarceva (erlotinib), Xalkori (crizotinib), Zykadia (certinib), and others. Among all, the Alecensa is anticipated to witness the highest growth during the forecast period, owing to the budding geographical penetration, rising awareness about the drugs, and the better progression-free survival rate as compared to Xalkori.
Furthermore, Tagrisso, a drug developed and sold by AstraZeneca, is also estimated to have a significant growth rate in the near future, accounting for its recent approvals in numerous geographical regions coupled with its increasing demand. For instance, in July 2020, The U.S. FDA granted breakthrough therapy designation to Tagrisso (osimertinib from AstraZeneca) for adjuvant treatment of certain patients with early-stage NSCLC, according to the agent’s manufacturer. Through this approval, osimertinib can be used by EGFR-mutated NSCLC patients after complete tumor resection.
Cancer Type Takeaway
In terms of cancer type, the worldwide industry is categorized into adenocarcinoma, large cell carcinoma, and squamous cell carcinoma. The adenocarcinoma segment is the most common type of NSCLC and is expected to have the majority of business shares, owing to the high prevalence of adenocarcinoma among all types of lung cancers. Adenocarcinoma type NSCLC develops at the edge of the lungs and in the cells in the airway, having slow growth.
Besides, this type of lung cancer can be treated easily. However, the squamous cell cancer type NSCLC is the fastest-growing vertical shortly. For instance, the updated data published by the LUNGevity Foundation, in June 2020, stated that lung adenocarcinoma accounts for about 40% of all lung cancers. Whereas, the squamous cell lung cancer accounted for more than 30% of all lung cancers.
Distribution Channel Takeaway
In terms of distribution channels, the worldwide industry is categorized into hospital pharmacies, online channels, retail pharmacies, and others. The hospital pharmacies segment tends to dominate the market share during the forecast period. The growth is acknowledged majorly due to the growing count of patients admitted to hospitals because of the rising prevalence of adenocarcinoma and squamous cell carcinoma.
Also, the hospital pharmacies segment focuses on preserving the standard of products related to this cancer for both out-patients and in-patients. In addition, the growing awareness about NSCLC and the developing healthcare infrastructures also aids in propelling the growth of hospital pharmacy vertical with maximum profits.
Regional Takeaway
Regionally, the overall industry is divided into North America, Middle East & Africa, Asia Pacific, Latin America, and Europe. North America dominates the segment, owing to the growing accumulating factors favoring the growth of lung cancer, including the count of smokers, exposure to toxins, and other elements of air pollution. Moreover, the adoption of advanced immunotherapies coupled with the growing demand for chemotherapy and other targeted therapy also aids in expanding the North America overall market size soon.
On the flip side, Asia Pacific accounts for the fastest-growing segment for the NSCLC market. Developing countries such as India and China are expecting growth in such therapeutic drugs, accounting for the increasing diagnosis of lung cancer. Other factors like the accessibility of advanced drugs coupled with the increasing investments by the key players in R&D of NSCLC therapy also positively influence the industrial growth. The World Health Organization’s latest report, published in February 2020, stated the count of people suffering from lung cancer to be 68,000 cases per year in India. Such factors accumulate the growth of the business in the APAC region.
COVID-19 Impact
The emergence of COVID-19 brought the world together to a standstill. The health crisis due to coronavirus also brought an unprecedented impact on numerous businesses across every vertical. This also resulted in decreasing the health care contact for patients. Besides, the patients suffering from lung cancer are a vulnerable population, as they are more prone to this deadly infection. However, the lockdown has limited the manufacturing and supply of drugs, which can be back on track with the unlocking process, as recommended by the regional governments.
Key Vendor Takeaway
The leading players of the market include AstraZeneca, Celgene Corporation, Sanofi S.A., F. Hoffmann-La Roche Ltd., GlaxoSmithKline plc, Merck & Co., Inc., Bristol Myers Squibb Company, Eli Lilly and Company, Novartis International AG, Pfizer Inc., and Takeda Pharmaceutical Company Limited.
The key players are actively adopting several strategies such as acquisition, geographical expansion, development of new and efficient therapeutics, etc. to maintain their position in the market. For instance, in August 2020, Daiichi Sankyo Company, Limited collaborated with AstraZeneca to evaluate the efficacy of patritumab deruxtecan (named U3-1402), and Osimertinib (TAGRISSO) in EGFR-mutated metastatic non-small cell lung cancer (NSCLC) patients.
The market size and forecast for each segment and sub-segments has been considered as below:
- Historical Year – 2016 to 2018
- Base Year – 2019
- Estimated Year – 2020
- Projected Year – 2021 to 2027
TARGET AUDIENCE
- Traders, Distributors, and Suppliers
- Manufacturers
- Government and Regional Agencies
- Research Organizations
- Consultants
- Distributors
SCOPE OF THE REPORT
The scope of this report covers the market by its major segments, which include as follows:
GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET KEY PLAYERS
- Hoffmann-La Roche Ltd.
- GlaxoSmithKline plc
- Merck & Co., Inc.
- Novartis International AG
- Celgene Corporation
- Eli Lilly and Company
- Pfizer Inc.
- Sanofi S.A.
- AstraZeneca PLC
- Bristol Myers Squibb Company
- Takeda Pharmaceutical Company Limited
GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET, BY DRUG CLASS
- Alecensa (alectinib)
- Alimta (pemetrexed)
- Avastin (bevacizumab)
- Cyramza (ramucirumab)
- Iressa (gefitinib)
- Opdivo (nivolumab)
- Tagrisso (osimertinib)
- Tarceva (erlotinib)
- Xalkori (crizotinib)
- Zykadia (certinib)
GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE
- Adenocarcinoma
- Large cell carcinoma
- Squamous Cell Carcinoma
GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL
- Hospital Pharmacy
- Online Channels
- Retail Pharmacy
- Others
GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET, BY REGION
- North America
- The U.S.
- Canada
- Europe
- Germany
- France
- Italy
- Spain
- United Kingdom
- Rest of Europe
- Asia Pacific
- India
- China
- South Korea
- Japan
- Singapore
- Rest of APAC
- Latin America
- Brazil
- Mexico
- Argentina
- Rest of LATAM
- The Middle East and Africa
- Saudi Arabia
- United Arab Emirates
- Rest of MEA
TABLE OF CONTENT
1. NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET OVERVIEW
1.1. Study Scope
2. EXECUTIVE SUMMARY
2.1. Market Snippet
2.1.1. Market Snippet by Drug Class
2.1.2. Market Snippet by Cancer Type
2.1.3. Market Snippet by Distribution Channel
2.1.4. Market Snippet by Region
2.2. Competitive Insights
3. NON-SMALL CELL LUNG CANCER THERAPEUTICS KEY MARKET TRENDS
3.1. Market Drivers
3.1.1. Impact Analysis of Market Drivers
3.2. Market Restraints
3.2.1. Impact Analysis of Market Restraints
3.3. Market Opportunities
3.4. Market Future Trends
4. NON-SMALL CELL LUNG CANCER THERAPEUTICS INDUSTRY STUDY
4.1. Porter’s Five Forces Analysis
4.2. Marketing Strategy Analysis
4.3. Growth Prospect Mapping
4.4. Regulatory Framework Analysis
5. NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET: COVID-19 IMPACT ANALYSIS
5.1. Pre-COVID-19 Impact Analysis
5.2. Post-COVID-19 Impact Analysis
5.2.1. Top Performing Segments
5.2.2. Marginal Growth Segments
5.2.3. Top Looser Segments
5.2.4. Marginal Loss Segments
6. NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET LANDSCAPE
6.1. Market Share Analysis, 2019
6.2. Key Innovators Analysis
6.3. Breakdown Data, by Key Manufacturer
6.3.1. Established Players’ Analysis
6.3.2. Emerging Players’ Analysis
7. NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET – BY DRUG CLASS
7.1. Overview
7.1.1. Segment Share Analysis, By Drug Class, 2020 & 2027 (%)
7.2. ALECENSA (alectinib)
7.2.1. Overview
7.2.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2016 – 2027, (US$ Million)
7.3. Alimta (pemetrexed)
7.3.1. Overview
7.3.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2016 – 2027, (US$ Million)
7.4. Avastin (bevacizumab)
7.4.1. Overview
7.4.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2016 – 2027, (US$ Million)
7.5. Cyramza (ramucirumab)
7.5.1. Overview
7.5.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2016 – 2027, (US$ Million)
7.6. Iressa (gefitinib)
7.6.1. Overview
7.6.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2016 – 2027, (US$ Million)
7.7. Opdivo (nivolumab)
7.7.1. Overview
7.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2016 – 2027, (US$ Million)
7.8. Tagrisso (osimertinib)
7.8.1. Overview
7.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2016 – 2027, (US$ Million)
7.9. Tarceva (erlotinib)
7.9.1. Overview
7.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2016 – 2027, (US$ Million)
7.10. Xalkori (crizotinib)
7.10.1. Overview
7.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2016 – 2027, (US$ Million)
7.11. Zykadia (certinib)
7.11.1. Overview
7.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2016 – 2027, (US$ Million)
7.12. Others
7.12.1. Overview
7.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2016 – 2027, (US$ Million)
8. NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET – BY CANCER TYPE
8.1. Overview
8.1.1. Segment Share Analysis, By Cancer Type, 2020 & 2027 (%)
8.2. Adenocarcinoma
8.2.1. Overview
8.2.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2016 – 2027, (US$ Million)
8.3. Large cell carcinoma
8.3.1. Overview
8.3.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2016 – 2027, (US$ Million)
8.4. Squamous Cell Carcinoma
8.4.1. Overview
8.4.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2016 – 2027, (US$ Million)
9. NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET – BY DISTRIBUTION CHANNEL
9.1. Overview
9.1.1. Segment Share Analysis, By Distribution Channel, 2020 & 2027 (%)
9.2. Hospital Pharmacy
9.2.1. Overview
9.2.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2016 – 2027, (US$ Million)
9.3. Online Channels
9.3.1. Overview
9.3.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2016 – 2027, (US$ Million)
9.4. Retail Pharmacy
9.4.1. Overview
9.4.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2016 – 2027, (US$ Million)
9.5. Others
9.5.1. Overview
9.5.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2016 – 2027, (US$ Million)
10. NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET– BY GEOGRAPHY
10.1. Introduction
10.1.1. Segment Share Analysis, By Geography, 2020 & 2027 (%)
10.2. North America
10.2.1. Overview
10.2.2. Key Manufacturers in North America
10.2.3. North America Market Size and Forecast, By Country, 2016 – 2027 (US$ Million)
10.2.4. North America Market Size and Forecast, By Drug Class, 2016 – 2027 (US$ Million)
10.2.5. North America Market Size and Forecast, By Cancer Type, 2016 – 2027 (US$ Million)
10.2.6. North America Market Size and Forecast, By Distribution Channel, 2016 – 2027 (US$ Million)
10.2.7. U.S.
10.2.7.1. Overview
10.2.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2016 – 2027, (US$ Million)
10.2.8. Canada
10.2.8.1. Overview
10.2.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2016 – 2027, (US$ Million)
10.3. Europe
10.3.1. Overview
10.3.2. Key Manufacturers in Europe
10.3.3. Europe Market Size and Forecast, By Country, 2016 – 2027 (US$ Million)
10.3.4. Europe Market Size and Forecast, By Drug Class, 2016 – 2027 (US$ Million)
10.3.5. Europe Market Size and Forecast, By Cancer Type, 2016 – 2027 (US$ Million)
10.3.6. Europe Market Size and Forecast, By Distribution Channel, 2016 – 2027 (US$ Million)
10.3.7. Germany
10.3.7.1. Overview
10.3.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2016 – 2027, (US$ Million)
10.3.8. Italy
10.3.8.1. Overview
10.3.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2016 – 2027, (US$ Million)
10.3.9. United Kingdom
10.3.9.1. Overview
10.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2016 – 2027, (US$ Million)
10.3.10. France
10.3.10.1. Overview
10.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2016 – 2027, (US$ Million)
10.3.11. Rest of Europe
10.3.11.1. Overview
10.3.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2016 – 2027, (US$ Million)
10.4. Asia Pacific (APAC)
10.4.1. Overview
10.4.2. Key Manufacturers in Asia Pacific
10.4.3. Asia Pacific Market Size and Forecast, By Country, 2016 – 2027 (US$ Million)
10.4.4. Asia Pacific Market Size and Forecast, By Drug Class, 2016 – 2027 (US$ Million)
10.4.5. Asia Pacific Market Size and Forecast, By Cancer Type, 2016 – 2027 (US$ Million)
10.4.6. Asia Pacific Market Size and Forecast, By Distribution Channel, 2016 – 2027 (US$ Million)
10.4.7. India
10.4.7.1. Overview
10.4.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2016 – 2027, (US$ Million)
10.4.8. China
10.4.8.1. Overview
10.4.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2016 – 2027, (US$ Million)
10.4.9. Japan
10.4.9.1. Overview
10.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2016 – 2027, (US$ Million)
10.4.10. South Korea
10.4.10.1. Overview
10.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2016 – 2027, (US$ Million)
10.4.11. Rest of APAC
10.4.11.1. Overview
10.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2016 – 2027, (US$ Million)
10.5. Latin America
10.5.1. Overview
10.5.2. Key Manufacturers in Latin America
10.5.3. Latin America Market Size and Forecast, By Country, 2016 – 2027 (US$ Million)
10.5.4. Latin America Market Size and Forecast, By Drug Class, 2016 – 2027 (US$ Million)
10.5.5. Latin America Market Size and Forecast, By Cancer Type, 2016 – 2027 (US$ Million)
10.5.6. Latin America Market Size and Forecast, By Distribution Channel, 2016 – 2027 (US$ Million)
10.5.7. Brazil
10.5.7.1. Overview
10.5.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2016 – 2027, (US$ Million)
10.5.8. Mexico
10.5.8.1. Overview
10.5.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2016 – 2027, (US$ Million)
10.5.9. Argentina
10.5.9.1. Overview
10.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2016 – 2027, (US$ Million)
10.5.10. Rest of LATAM
10.5.10.1. Overview
10.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2016 – 2027, (US$ Million)
10.6. Middle East and Africa
10.6.1. Overview
10.6.2. Key Manufacturers in Middle East and Africa
10.6.3. Middle East and Africa Market Size and Forecast, By Country, 2016 – 2027 (US$ Million)
10.6.4. Middle East and Africa Market Size and Forecast, By Drug Class, 2016 – 2027 (US$ Million)
10.6.5. Middle East and Africa Market Size and Forecast, By Cancer Type, 2016 – 2027 (US$ Million)
10.6.6. Middle East and Africa Market Size and Forecast, By Distribution Channel, 2016 – 2027 (US$ Million)
10.6.7. Saudi Arabia
10.6.7.1. Overview
10.6.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2016 – 2027, (US$ Million)
10.6.8. United Arab Emirates
10.6.8.1. Overview
10.6.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2016 – 2027, (US$ Million)
11. KEY VENDOR ANALYSIS
11.1. Competitive Dashboard
11.2. Company Profiles
11.2.1. AstraZeneca PLC
11.2.1.1. Company Snapshot
11.2.1.2. Financial Performance
11.2.1.3. Product Benchmarking
11.2.1.4. Strategic Initiatives
11.2.2. Bristol Myers Squibb Company
11.2.3. Celgene Corporation
11.2.4. Eli Lilly and Company
11.2.5. F. Hoffmann-La Roche Ltd.
11.2.6. GlaxoSmithKline plc
11.2.7. Merck & Co., Inc.
11.2.8. Novartis International AG
11.2.9. Pfizer Inc.
11.2.10. Sanofi S.A.
11.2.11. Takeda Pharmaceutical Company Limited
12. 360 DEGREE ANALYSTVIEW
13. APPENDIX
13.1. Research Methodology
13.2. References
13.3. Abbreviations
13.4. Disclaimer
13.5. Contact Us
List of Tables
TABLE List of data sources
TABLE Market drivers; Impact Analysis
TABLE Market restraints; Impact Analysis
TABLE Non-small cell lung cancer therapeutics market: Drug Classs Snapshot (2019)
TABLE Segment Dashboard; Definition and Scope, by Drug Classs
TABLE Global non-small cell lung cancer therapeutics market, by Drug Classs 2016-2027 (USD Million)
TABLE Non-small cell lung cancer therapeutics market: Cancer Type Snapshot (2019)
TABLE Segment Dashboard; Definition and Scope, by Cancer Type
TABLE Global non-small cell lung cancer therapeutics market, by Cancer Type 2016-2027 (USD Million)
TABLE Non-small cell lung cancer therapeutics market: Distribution Channel Snapshot (2019)
TABLE Segment Dashboard; Definition and Scope, by Distribution Channel
TABLE Global non-small cell lung cancer therapeutics market, by Distribution Channel 2016-2027 (USD Million)
TABLE Non-small cell lung cancer therapeutics market: Regional snapshot (2019)
TABLE Segment Dashboard; Definition and Scope, by Region
TABLE Global non-small cell lung cancer therapeutics market, by Region 2016-2027 (USD Million)
TABLE North America non-small cell lung cancer therapeutics market, by Country, 2016-2027 (USD Million)
TABLE North America non-small cell lung cancer therapeutics market, by Drug Classs, 2016-2027 (USD Million)
TABLE North America non-small cell lung cancer therapeutics market, by Cancer Type, 2016-2027 (USD Million)
TABLE North America non-small cell lung cancer therapeutics market, by Distribution Channel, 2016-2027 (USD Million)
TABLE Europe non-small cell lung cancer therapeutics market, by Country, 2016-2027 (USD Million)
TABLE Europe non-small cell lung cancer therapeutics market, by Drug Classs, 2016-2027 (USD Million)
TABLE Europe non-small cell lung cancer therapeutics market, by Cancer Type, 2016-2027 (USD Million)
TABLE Europe non-small cell lung cancer therapeutics market, by Distribution Channel, 2016-2027 (USD Million)
TABLE Asia Pacific non-small cell lung cancer therapeutics market, by Country, 2016-2027 (USD Million)
TABLE Asia Pacific non-small cell lung cancer therapeutics market, by Drug Classs, 2016-2027 (USD Million)
TABLE Asia Pacific non-small cell lung cancer therapeutics market, by Cancer Type, 2016-2027 (USD Million)
TABLE Asia Pacific non-small cell lung cancer therapeutics market, by Distribution Channel, 2016-2027 (USD Million)
TABLE Latin America non-small cell lung cancer therapeutics market, by Country, 2016-2027 (USD Million)
TABLE Latin America non-small cell lung cancer therapeutics market, by Drug Class, 2016-2027 (USD Million)
TABLE Latin America non-small cell lung cancer therapeutics market, by Cancer Type, 2016-2027 (USD Million)
TABLE Latin America non-small cell lung cancer therapeutics market, by Distribution Channel, 2016-2027 (USD Million)
TABLE Middle East and Africa non-small cell lung cancer therapeutics market, by Country, 2016-2027 (USD Million)
TABLE Middle East and Africa non-small cell lung cancer therapeutics market, by Drug Class, 2016-2027 (USD Million)
TABLE Middle East and Africa non-small cell lung cancer therapeutics market, by Drug Class, 2016-2027 (USD Million)
TABLE Middle East and Africa non-small cell lung cancer therapeutics market, by Drug Class, 2016-2027 (USD Million)
List of Figures
FIGURE Non-small cell lung cancer therapeutics market segmentation
FIGURE Market research methodology
FIGURE Value chain analysis
FIGURE Porter’s Five Forces Analysis
FIGURE Market Attractiveness Analysis
FIGURE COVID-19 Impact Analysis
FIGURE Pre & Post COVID-19 Impact Comparision Study
FIGURE Competitive Landscape; Key company market share analysis, 2019
FIGURE Drug Class segment market share analysis, 2020 & 2027
FIGURE Drug Class segment market size forecast and trend analysis, 2016 to 2027 (USD Million)
FIGURE ALECENSA (alectinib) market size forecast and trend analysis, 2016 to 2027 (USD Million)
FIGURE Alimta (pemetrexed) market size forecast and trend analysis, 2016 to 2027 (USD Million)
FIGURE Avastin (bevacizumab) market size forecast and trend analysis, 2016 to 2027 (USD Million)
FIGURE Cyramza (ramucirumab) market size forecast and trend analysis, 2016 to 2027 (USD Million)
FIGURE Iressa (gefitinib) market size forecast and trend analysis, 2016 to 2027 (USD Million)
FIGURE Opdivo (nivolumab) market size forecast and trend analysis, 2016 to 2027 (USD Million)
FIGURE Tagrisso (osimertinib) market size forecast and trend analysis, 2016 to 2027 (USD Million)
FIGURE Tarceva (erlotinib) market size forecast and trend analysis, 2016 to 2027 (USD Million)
FIGURE Xalkori (crizotinib) market size forecast and trend analysis, 2016 to 2027 (USD Million)
FIGURE Zykadia (certinib) market size forecast and trend analysis, 2016 to 2027 (USD Million)
FIGURE Others market size forecast and trend analysis, 2016 to 2027 (USD Million)
FIGURE Cancer Type segment market share analysis, 2020 & 2027
FIGURE Cancer Type segment market size forecast and trend analysis, 2016 to 2027 (USD Million)
FIGURE Adenocarcinoma market size forecast and trend analysis, 2016 to 2027 (USD Million)
FIGURE Large cell carcinoma market size forecast and trend analysis, 2016 to 2027 (USD Million)
FIGURE Squamous Cell Carcinoma market size forecast and trend analysis, 2016 to 2027 (USD Million)
FIGURE Distribution Channel segment market share analysis, 2020 & 2027
FIGURE Distribution Channel segment market size forecast and trend analysis, 2016 to 2027 (USD Million)
FIGURE Hospital Pharmacy market size forecast and trend analysis, 2016 to 2027 (USD Million)
FIGURE Online Channels market size forecast and trend analysis, 2016 to 2027 (USD Million)
FIGURE Retail Pharmacy market size forecast and trend analysis, 2016 to 2027 (USD Million)
FIGURE Others market size forecast and trend analysis, 2016 to 2027 (USD Million)
FIGURE Regional segment market share analysis, 2020 & 2027
FIGURE Regional segment market size forecast and trend analysis, 2016 to 2027 (USD Million)
FIGURE North America non-small cell lung cancer therapeutics market share and leading players, 2019
FIGURE Europe non-small cell lung cancer therapeutics market share and leading players, 2019
FIGURE Asia Pacific non-small cell lung cancer therapeutics market share and leading players, 2019
FIGURE Latin America non-small cell lung cancer therapeutics market share and leading players, 2019
FIGURE Middle East and Africa non-small cell lung cancer therapeutics market share and leading players, 2019
FIGURE North America market share analysis by country, 2019
FIGURE U.S. non-small cell lung cancer therapeutics market size, forecast and trend analysis, 2016 to 2027 (USD Million)
FIGURE Canada non-small cell lung cancer therapeutics market size, forecast and trend analysis, 2016 to 2027 (USD Million)
FIGURE Europe non-small cell lung cancer therapeutics market share analysis by country, 2019
FIGURE Germany non-small cell lung cancer therapeutics market size, forecast and trend analysis, 2016 to 2027 (USD Million)
FIGURE Spain non-small cell lung cancer therapeutics market size, forecast and trend analysis, 2016 to 2027 (USD Million)
FIGURE Italy non-small cell lung cancer therapeutics market size, forecast and trend analysis, 2016 to 2027 (USD Million)
FIGURE UK non-small cell lung cancer therapeutics market size, forecast and trend analysis, 2016 to 2027 (USD Million)
FIGURE France non-small cell lung cancer therapeutics market size, forecast and trend analysis, 2016 to 2027 (USD Million)
FIGURE Rest of the Europe non-small cell lung cancer therapeutics market size, forecast and trend analysis, 2016 to 2027 (USD Million)
FIGURE Asia Pacific non-small cell lung cancer therapeutics market share analysis by country, 2019
FIGURE India non-small cell lung cancer therapeutics market size, forecast and trend analysis, 2016 to 2027 (USD Million)
FIGURE China non-small cell lung cancer therapeutics market size, forecast and trend analysis, 2016 to 2027 (USD Million)
FIGURE Japan non-small cell lung cancer therapeutics market size, forecast and trend analysis, 2016 to 2027 (USD Million)
FIGURE South Korea non-small cell lung cancer therapeutics market size, forecast and trend analysis, 2016 to 2027 (USD Million)
FIGURE Singapore non-small cell lung cancer therapeutics market size, forecast and trend analysis, 2016 to 2027 (USD Million)
FIGURE Rest of APAC non-small cell lung cancer therapeutics market size, forecast and trend analysis, 2016 to 2027 (USD Million)
FIGURE Latin America non-small cell lung cancer therapeutics market size, forecast and trend analysis, 2016 to 2027 (USD Million)
FIGURE Latin America non-small cell lung cancer therapeutics market share analysis by country, 2019
FIGURE Brazil non-small cell lung cancer therapeutics market size, forecast and trend analysis, 2016 to 2027 (USD Million)
FIGURE Mexico non-small cell lung cancer therapeutics market size, forecast and trend analysis, 2016 to 2027 (USD Million)
FIGURE Argentina non-small cell lung cancer therapeutics market size, forecast and trend analysis, 2016 to 2027 (USD Million)
FIGURE Rest of LATAM non-small cell lung cancer therapeutics market size, forecast and trend analysis, 2016 to 2027 (USD Million)
FIGURE Middle East and Africa non-small cell lung cancer therapeutics market size, forecast and trend analysis, 2016 to 2027 (USD Million)
FIGURE Middle East and Africa non-small cell lung cancer therapeutics market share analysis by country, 2019
FIGURE Saudi Arabia non-small cell lung cancer therapeutics market size, forecast and trend analysis, 2016 to 2027 (USD Million)
FIGURE United Arab Emirates non-small cell lung cancer therapeutics market size, forecast and trend analysis, 2016 to 2027 (USD Million)
